Development Phase

How far has industry come with development of each modality?

What phase(s) of development are the therapeutics you are working with currently in?

In this section we look at the development phase that different modalities are in. As this chart shows, the majority of all respondents are currently in discovery/pre- clinical, with fewer and fewer in each stage - just 3% of respondents are working on therapeutics in Phase IV.

What phase(s) of development are the therapeutics you are working with currently in? - BY MODALITY (Click on any of the charts for a closer view)

mAbs

Bispecifics

Protein therapeutics

Looking more closely at the stage of development of different modalities, it is a similar story for most. However, protein therapeutics appear to be slightly more advanced amongst respondents, with 36% in Phase II-IV trials, versus just 21% of those working with bispecifics.

What phase(s) of development are the therapeutics you are working with currently in? - BY MODALITY (Click on any of the charts for a closer view)

ADCs

CAR-T/Cellular therapies

Immuno-oncology: Checkpoints

Immuno-oncology checkpoints has the highest proportion of therapies in Phase III and IV, with 17% of respondents working on them at that stage of development. This is contrast to just 6% of those working on CAR-T/cellular therapies.